GENMAB a/S

Genmab A/ shows solid March gains, outpacing peers with a bullish analyst consensus and low short interest – a strong outlook for its antibody pipeline.

Genmab’s share price climbs 2.4% as analysts stay bullish, citing strong antibody‑therapeutic pipeline and Denmark’s thriving biopharma scene.